1. Home
  2. ENSC vs GNLN Comparison

ENSC vs GNLN Comparison

Compare ENSC & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • GNLN
  • Stock Information
  • Founded
  • ENSC 2003
  • GNLN 2005
  • Country
  • ENSC United States
  • GNLN United States
  • Employees
  • ENSC N/A
  • GNLN N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • GNLN Durable Goods
  • Sector
  • ENSC Health Care
  • GNLN Consumer Discretionary
  • Exchange
  • ENSC Nasdaq
  • GNLN Nasdaq
  • Market Cap
  • ENSC 2.9M
  • GNLN 2.3M
  • IPO Year
  • ENSC N/A
  • GNLN 2019
  • Fundamental
  • Price
  • ENSC $3.29
  • GNLN $0.01
  • Analyst Decision
  • ENSC
  • GNLN
  • Analyst Count
  • ENSC 0
  • GNLN 0
  • Target Price
  • ENSC N/A
  • GNLN N/A
  • AVG Volume (30 Days)
  • ENSC 4.9M
  • GNLN 39.7M
  • Earning Date
  • ENSC 05-12-2025
  • GNLN 03-21-2025
  • Dividend Yield
  • ENSC N/A
  • GNLN N/A
  • EPS Growth
  • ENSC N/A
  • GNLN N/A
  • EPS
  • ENSC N/A
  • GNLN N/A
  • Revenue
  • ENSC $5,210,031.00
  • GNLN $13,275,000.00
  • Revenue This Year
  • ENSC N/A
  • GNLN $1,541.21
  • Revenue Next Year
  • ENSC N/A
  • GNLN N/A
  • P/E Ratio
  • ENSC N/A
  • GNLN N/A
  • Revenue Growth
  • ENSC 133.58
  • GNLN N/A
  • 52 Week Low
  • ENSC $1.62
  • GNLN $0.01
  • 52 Week High
  • ENSC $14.67
  • GNLN $21.80
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 55.92
  • GNLN 18.47
  • Support Level
  • ENSC $3.02
  • GNLN $0.21
  • Resistance Level
  • ENSC $4.85
  • GNLN $0.29
  • Average True Range (ATR)
  • ENSC 0.40
  • GNLN 0.03
  • MACD
  • ENSC 0.27
  • GNLN -0.00
  • Stochastic Oscillator
  • ENSC 51.70
  • GNLN 0.32

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.

Share on Social Networks: